Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | EVP & General Manager US | July 16, 2025 | July 17, 2025 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date July 16, 2025 · Filed July 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,149 |
Reported balance
After 2025-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-07-16 · Sale · Disposed 1,340 · Balance 35,149 F1: This includes an aggregate of 35,136 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This includes an aggregate of 35,136 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENOMIC HEALTH INC
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 1
1 source rowRow 1 · 2019-11-08 · Disposition to issuer · Disposed 397 · Balance 0 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $10,989 and 178 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.20 · Expires 2029-04-16 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $13,463 and 220 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $10,989 and 178 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F2: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $13,463 and 220 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001213900-26-069244 · marketforms-73181.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2036-06-14 F1 · derivative.exercise_date: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| July 16, 2025 Filed Jul 17, 2025 20:06 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,340 | $68.36 | $91,602.40 |
DisclosureSEC source: 0000879169-25-000093 · wk-form4_1752782756.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,149 F1 · balance_after: This includes an aggregate of 35,136 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 20:02 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,141 | $68.25 | $77,873.25 |
DisclosureSEC source: 0000879169-25-000080 · wk-form4_1752696123.xml · nonDerivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,489 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 35,136 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 20:02 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,192 | $69.86 | $83,273.12 |
DisclosureSEC source: 0000879169-25-000080 · wk-form4_1752696123.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,630 Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 20:02 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 922 | $69.98 | $64,521.56 |
DisclosureSEC source: 0000879169-25-000080 · wk-form4_1752696123.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,822 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 03, 2025 Filed Jul 7, 2025 20:46 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 10,903 | $68.15 | $743,039.45 |
DisclosureSEC source: 0000879169-25-000074 · wk-form4_1751921143.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,744 F2 · balance_after: This includes an aggregate of 39,731 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 20:46 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 9,055 | $68.17 | $617,279.35 |
DisclosureSEC source: 0000879169-25-000074 · wk-form4_1751921143.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,647 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001213900-25-054282 · marketforms-69812.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:52 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 14,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-016582 · wk-form4_1743713556.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,702 F2 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on the third anniversary of the July 2, 2022 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2022 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded. F3 · balance_after: This includes an aggregate of 59,689 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:52 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 11,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-016582 · wk-form4_1743713556.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,726 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. While Dr. Flannelly will retire from the Company on July 31, 2025, the earned shares will vest on November 30, 2025 in line with the retirement provisions of the plan. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, achievement of specified Opzelura performance goals. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:01 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 19,147 | $67.68 | $1,295,868.96 |
DisclosureSEC source: 0001628280-25-013444 · wk-form4_1742328060.xml · nonDerivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,567 F1 · balance_after: This includes an aggregate of 33,554 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:01 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 199 | $67.88 | $13,508.12 |
DisclosureSEC source: 0001628280-25-013444 · wk-form4_1742328060.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,714 Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:01 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 461 | $67.85 | $31,278.85 |
DisclosureSEC source: 0001628280-25-013444 · wk-form4_1742328060.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,913 Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 21:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 20,144 | $0.00 Strike: $71.93 | $0.00 |
DisclosureSEC source: 0000879169-25-000038 · wk-form4_1737580111.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,144 Underlying: Common Stock · 20,144 shares Expires 2035-01-16 F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 20:33 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 3,158 | $72.46 | $228,828.68 |
DisclosureSEC source: 0000879169-25-000019 · wk-form4_1737146019.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,374 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 33,554 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 18:19 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,510 | $72.11 | $108,886.10 |
DisclosureSEC source: 0000879169-24-000179 · wk-form4_1733941156.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,532 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 44,595 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 17:48 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,256 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · derivative · entry 6 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,256 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 17:48 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,424 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · derivative · entry 5 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,424 shares Expires 2029-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 17:48 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 2,256 | $78.21 | $176,441.76 |
DisclosureSEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · nonDerivative · entry 4 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,042 F1 · balance_after: This includes an aggregate of 46,105 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 17:48 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,424 | $82.00 | $116,768.00 |
DisclosureSEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · nonDerivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,298 Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 17:48 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 2,256 | $68.62 | $154,806.72 |
DisclosureSEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 17:48 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 1,424 | $72.27 | $102,912.48 |
DisclosureSEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2024 Filed Jul 17, 2024 16:24 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,306 | $64.19 | $83,832.14 |
DisclosureSEC source: 0000879169-24-000130 · wk-form4_1721233433.xml · nonDerivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,042 F3 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 46,105 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:24 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 22,205 | $0.00 Strike: $64.25 | $0.00 |
DisclosureSEC source: 0000879169-24-000130 · wk-form4_1721233433.xml · derivative · entry 4 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,205 Underlying: Common Stock · 22,205 shares Expires 2034-07-14 F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:24 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,111 | $64.25 | $71,381.75 |
DisclosureSEC source: 0000879169-24-000130 · wk-form4_1721233433.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,348 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:24 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 9,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000130 · wk-form4_1721233433.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,459 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 16:35 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 8,148 | $60.00 | $488,880.00 |
DisclosureSEC source: 0000879169-24-000118 · wk-form4_1720715703.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,534 F1 · balance_after: This includes an aggregate of 38,597 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 16:19 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 7,695 | $59.02 | $454,158.90 |
DisclosureSEC source: 0000879169-24-000115 · wk-form4_1720023565.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,682 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 38,597 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:17 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 19,164 | $60.00 | $1,149,840.00 |
DisclosureSEC source: 0000879169-24-000098 · wk-form4_1718381865.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,377 F1 · balance_after: This includes an aggregate of 55,340 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 22:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001213900-24-051382 · marketforms-66265.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 17:47 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 7,377 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000055 · wk-form4_1708105638.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,080 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 14, 2024. The earned shares will vest on the third anniversary of the July 2, 2021 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2021 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded. F2 · balance_after: This includes an aggregate of 55,340 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 18:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 21,843 | $0.00 Strike: $61.18 | $0.00 |
DisclosureSEC source: 0000879169-24-000027 · wk-form4_1705946452.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,843 Underlying: Common Stock · 21,843 shares Expires 2034-01-17 F1 · derivative.exercise_date: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 22:31 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 3,675 | $61.48 | $225,939.00 |
DisclosureSEC source: 0000879169-24-000016 · wk-form4_1705703485.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,703 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 47,963 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 20,275 | $0.00 Strike: $61.76 | $0.00 |
DisclosureSEC source: 0001209191-23-042546 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,275 Underlying: Common Stock · 20,275 shares Expires 2033-07-13 F3 · derivative.exercise_date: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 9,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042546 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,378 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Barry Flannelly's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 14, 2023 RSU Grant, this includes an aggregate of 59,445 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 6,304 | $62.08 | $391,352.32 |
DisclosureSEC source: 0001209191-23-041509 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,710 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 49,777 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001213900-23-047465 · ownership.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 19,354 | $0.00 Strike: $83.20 | $0.00 |
DisclosureSEC source: 0001209191-23-004560 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,354 Underlying: Common Stock · 19,354 shares Expires 2033-01-19 F3 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 the remainder vesting monthly over three years. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 4,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004560 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,654 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on January 20, 2023. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: This includes an aggregate of 66,790 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. The aggregate amount also includes the additional Performance Stock Units earned on January 20, 2023. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:00 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 2,873 | $79.38 | $228,058.74 |
DisclosureSEC source: 0001209191-22-041761 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,674 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 48,281 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 20:06 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 3,506 | $79.25 | $277,850.50 |
DisclosureSEC source: 0001209191-22-041066 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,547 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2022 RSU Grant, this includes an aggregate of 48,281 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document |
| July 02, 2022 Filed Jul 6, 2022 20:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 18,332 | $0.00 Strike: $77.67 | $0.00 |
DisclosureSEC source: 0001209191-22-041066 · doc4.xml · derivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,332 Underlying: Common Stock · 18,332 shares Expires 2032-07-01 F4 · derivative.exercise_date: Beginning July 2, 2022, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2022 Filed Jul 6, 2022 20:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 13,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-041066 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,053 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Barry Flannelly's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001213900-22-031995 · ownership.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 21,348 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-22-024136 · doc4.xml · derivative · entry 8 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,348 shares Expires 2029-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,516 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-22-024136 · doc4.xml · derivative · entry 7 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,516 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:10 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,248 | $82.96 | $103,534.08 |
DisclosureSEC source: 0001209191-22-024136 · doc4.xml · nonDerivative · entry 6 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,163 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 64,148 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:10 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 881 | $82.96 | $73,087.76 |
DisclosureSEC source: 0001209191-22-024136 · doc4.xml · nonDerivative · entry 5 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,411 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:10 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 21,348 | $84.00 | $1,793,232.00 |
DisclosureSEC source: 0001209191-22-024136 · doc4.xml · nonDerivative · entry 4 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,292 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 21,348 | $72.27 | $1,542,819.96 |
DisclosureSEC source: 0001209191-22-024136 · doc4.xml · nonDerivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.